Revolutionizing Psoriasis Treatment: Wynzora Added to PBS
Are you tired of the constant itching and flaking of psoriasis? Well, get ready for some exciting news! The Pharmaceutical Benefits Scheme (PBS) has recently made a significant change that will impact the lives of over 140,000 Australians suffering from chronic stable plaque-type psoriasis vulgaris. This groundbreaking development introduces Wynzora, a new treatment that promises to bring relief and improve the quality of life for these individuals.
But here's where it gets controversial... While Wynzora is now accessible, its cost remains a concern. Without subsidy, patients will have to pay around $65 per script. This might be a burden for some, but the good news is that the Federal Government has also expanded access to another treatment, dapagliflozin (sold as Forxiga), for those living with chronic kidney disease. This move is expected to benefit 65,000 people, ensuring that more individuals can access the care they need.
Now, let's dive into the details. Wynzora, a combination of calcipotriol and betamethasone dipropionate, is designed to slow the overgrowth of skin cells and reduce inflammation and irritation. This treatment is a game-changer for those who have been struggling with the chronic condition. The medication is now listed for the treatment of chronic stable plaque-type psoriasis vulgaris, offering a glimmer of hope for improved management of this debilitating disease.
But it's not just about Wynzora. The Federal Government has also taken steps to make another treatment more accessible. Vanzacaftor with tezacaftor and deutivacaftor (sold as Alyftrek) has been added to the PBS for the first time, targeting individuals with at least one mutation in the CF transmembrane conductance regulator (CFTR) gene that responds to treatment. This medication, taken orally once daily for those aged six years and older, helps increase the amount of functioning CFTR proteins, offering a new avenue for those living with cystic fibrosis.
And this is the part most people miss... The addition of Alyftrek to the PBS is a significant step forward, as it follows the listing of elexacaftor/tezacaftor/ivacaftor (sold as Trikafta) last July. This move has the potential to give more than 2650 patients access to a treatment that was previously priced at around $250,000, a cost described as 'an impossible price' by Federal Health and Ageing Minister Mark Butler. So, while the PBS continues to expand access to essential medications, it's crucial to address the concerns of patients and ensure that these treatments are affordable and accessible to all who need them.
Now, it's your turn to share your thoughts! Do you think the PBS is doing enough to make essential medications more affordable and accessible? Or is there more that can be done? Share your agreement or disagreement in the comments below, and let's spark a conversation about this important issue.
